Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
about
Novel NMDA receptor modulators: an updateDrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsComprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affectPseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.Diagnosing pseudobulbar affect in traumatic brain injury.Pseudobulbar affect: an under-recognized and under-treated neurological disorder.Pseudobulbar affect: burden of illness in the USA.Pseudobulbar affect: prevalence and management.Multidisciplinary Interventions in Motor Neuron Disease.New considerations in the design of clinical trials for amyotrophic lateral sclerosisPRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditionsA study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers.Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing.Dextromethorphan/quinidine: in pseudobulbar affect.Current concepts in the pharmacotherapy of pseudobulbar affect.EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.A systematic review of pharmacological pain management in multiple sclerosis.Crying and suicidal, but not depressed. Pseudobulbar affect in multiple sclerosis successfully treated with valproic acid: Case report and literature review.Assessment of disease progression and functional benefit in neurodegenerative disease: can we tell the difference?Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.Neuronal Dysregulation in Stroke-Associated Pseudobulbar Affect (PBA): Diagnostic Scales and Current Treatment OptionsPseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP).Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine.Outcome measures in amyotrophic lateral sclerosis clinical trialsLaughter, crying and sadness in ALS.Dextromethorphan-Quinidine for Agitation in Alzheimer Disease.Mechanism of action of dextromethorphan/quinidine:comparison with ketamine.Introduction to supplement: the current status of treatment for ALS.Improving symptom management for people with amyotrophic lateral sclerosis.Effects of dextromethorphan on glial cell function: proliferation, maturation, and protection from cytotoxic molecules.Symptom management in amyotrophic lateral sclerosis: We can do better.Management of post-stroke mood and emotional disturbances.Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale).Amyotrophic lateral sclerosis
P2860
Q26849614-18140063-6E2D-48F5-97E4-5D2DFC9A6868Q28071256-51FBCB99-2EB0-4462-83E3-1A9D27C60C25Q30365902-0B66C0F3-8A83-4D6C-9902-A89E35369E80Q30634431-BF87C100-2958-4507-8B5B-3C7742C73C43Q33838839-323ADD23-3FBA-49F2-AB37-3D2B6C7BE7B9Q34026748-4504F537-A437-48DA-BCFC-FAF68AC68477Q34354384-FE9592B1-D7BD-459A-96C0-1396928DA87FQ34630034-2B0A7CCE-CC18-4080-AD9C-9496DECD54BFQ34641967-A0CDD2A4-B66E-49E2-B13E-8C3707C857F8Q34658447-8A167E9B-A62C-4166-8D75-94EAB613A915Q35623262-FCC8B0D5-57EA-4FA8-9BD6-9D0BF581E035Q35910744-AC8540E3-5CB7-4F87-B04C-6C790AB00BE5Q36045307-BF92E203-EA1B-43F3-98EF-86B304B959B3Q36551001-308A1E60-333B-494C-8462-5DC93980EB8FQ37021521-6B4EBA9C-2A38-4CB4-8DA4-AAC366949375Q37081555-C18319B3-A717-42C1-A610-4CC14EA4C8F7Q37863094-3D072637-E7F9-42D5-A8DC-91522B45455CQ37895256-7BF2C8F3-5C34-4304-B80A-06E8E6F75B11Q37931374-A27EB7B1-66C7-49F5-869F-EA6FACAC14FAQ38148499-25BB5B4F-F8AC-4FA3-8521-6D5DB1679653Q38219309-854B5FDE-7F65-4D3D-BEA0-CC92484092C6Q38219475-E4D92D2A-DF61-49EA-8EAD-EAB4106BD52EQ38270903-840ABDFE-AD0D-4F3C-BF13-BDA726FDA876Q38401900-C1C6E527-9CA1-4013-8D6B-2D0EBD009B5BQ38676032-A8BE61A0-637F-47A1-A42A-3B0AAE66E5ACQ39530443-C60593F6-3F7A-486F-9D44-3192CC33DE18Q41009555-B23D7555-0683-47D9-BCD0-12BD475FC0DCQ41164001-FDF26084-8D56-445C-A337-ED751CFA6E2FQ41837997-15EBA62F-3D3C-47BC-9731-0CA72A2E62D3Q42275960-E61F1D8A-F21D-41FA-915B-8D1082D4A54CQ42318071-EEAF7FC6-C2F9-44E7-B907-240AC8EAD9F8Q46105473-DD794D80-6E73-4982-B2A3-6A7B64F1FA49Q46135234-D3EB5EC6-AAEF-475A-9564-40E9E7BB2BA6Q46604820-3CDBF549-B027-49D6-A701-A0CF51CBEDB8Q46932015-6B4E3A5F-837B-40CB-92F9-06D5CA0A6C1EQ47102766-F95A15B5-304D-4F3E-A441-F83861779233Q47731936-26351AB5-4D66-437A-881B-66A5DF0CF24EQ55664870-792CCE76-3C2B-4EDC-88A7-C2798021FC16Q56531747-DFCD2582-8F5C-47E4-A2BF-08DC0FE1F9D4
P2860
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
@ast
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
@en
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
@nl
type
label
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
@ast
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
@en
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
@nl
prefLabel
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
@ast
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
@en
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
@nl
P2093
P2860
P3181
P356
P1433
P1476
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
@en
P2093
Adrian Hepner
Benjamin Rix Brooks
Daniel Wynn
Erik P Pioro
Jeffrey Cummings
Randall Kaye
Randolph Schiffer
Ronald A Thisted
P2860
P304
P3181
P356
10.1002/ANA.22093
P407
P577
2010-11-01T00:00:00Z